AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Citius Pharmaceuticals Inc

Healthcare US CTXR


Last update at 2024-02-22T20:53:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Income before tax -33.06465M -23.05443M -17.54809M -15.56214M -12.53664M
Minority interest - - - - -
Net income -33.64065M -23.12519M -17.67396M -15.57859M -12.53664M
Selling general administrative 15.66M 11.29M 8.90M 7.00M 7.23M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.18M 0.16M 0.15M 0.00089M 0.00175M
Ebit -33.31605M -23.53189M -17.71069M -15.59836M -12.52080M
Ebitda -32.88497M -23.04528M -17.38005M -15.54481M -12.51905M
Depreciation and amortization 0.43M 0.49M 0.33M 0.05M 0.00175M
Non operating income net other - 0.49M 0.18M 0.05M 1.27M
Operating income -33.31605M -23.53189M -17.71069M -15.59836M -13.78914M
Other operating expenses 33.32M 23.53M 17.71M 15.60M 13.79M
Interest expense 0.25M 0.01M 0.02M 0.02M 0.02M
Tax provision 0.58M - 0.00000M 0.00000M 0.00000M
Interest income 0.25M 0.26M 0.07M 0.05M 0.00000M
Net interest income 0.25M 0.25M 0.05M 0.04M -0.01584M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.58M 0.07M 0.13M 0.02M 1.28M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 33.32M 23.53M 17.71M 15.60M 13.79M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.25M 0.48M 0.16M 0.04M 1.27M
Discontinued operations - - - - -
Net income from continuing ops -33.64065M -23.05443M -17.54809M -15.56214M -12.53664M
Net income applicable to common shares -33.64065M -24.50531M -17.54809M -15.56214M -12.53664M
Preferred stock and other adjustments - 1.45M - - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Total assets 114.00M 142.43M 43.77M 28.99M 31.05M
Intangible assets 59.40M 59.40M 19.40M 19.40M 19.40M
Earning assets - - - - -
Other current assets 2.85M 2.74M 0.12M 0.05M 0.06M
Total liab 10.57M 9.65M 10.10M 4.61M 3.18M
Total stockholder equity 102.83M 132.18M 33.67M 24.38M 27.87M
Deferred long term liab 5.56M 4.99M 4.99M - -
Other current liab 3.17M 2.53M 1.91M 1.72M 1.44M
Common stock 0.15M 0.15M 0.06M 0.03M 0.02M
Capital stock 0.15M 0.15M 0.06M 0.03M 0.02M
Retained earnings -129.68847M -96.04782M -70.59387M -55.81998M -40.25784M
Other liab 5.56M 4.99M 4.99M 4.99M -
Good will 9.35M 9.35M 9.35M 1.59M 1.59M
Other assets 0.04M 0.04M 0.06M 0.06M 0.00217M
Cash 41.71M 70.07M 13.86M 7.89M 9.18M
Cash and equivalents - - - - -
Total current liabilities 4.53M 3.98M 4.10M 4.61M 3.18M
Current deferred revenue - - - - -
Net debt -41.03346M -69.21747M -12.50773M -7.72083M -9.01103M
Short term debt 0.20M 0.18M 0.33M 0.17M 0.17M
Short long term debt - - 0.17M 0.17M 0.17M
Short long term debt total 0.68M 0.86M 1.35M 0.17M 0.17M
Other stockholder equity 232.37M 228.08M 104.21M 80.17M 68.11M
Property plant equipment 0.00410M 0.00702M 0.00158M 0.00059M 0.00148M
Total current assets 44.56M 72.81M 13.98M 7.94M 10.06M
Long term investments - - - - -
Net tangible assets 102.83M 132.18M 33.67M -1.59392M 6.88M
Short term investments - - - - -
Net receivables - - - - 0.82M
Long term debt - - 0.16M - -
Inventory - - - - -
Accounts payable 1.17M 1.28M 1.86M 2.71M 1.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 0.60M 0.60M - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity 0.15M 0.15M 0.06M 0.03M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity -129.68847M -96.04782M -70.59387M -55.81998M -40.25784M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 39.97M 0.04M 0.06M 0.06M 0.00217M
Deferred long term asset charges - - - - -
Non current assets total 69.44M 69.61M 29.79M 21.04M 20.99M
Capital lease obligations 0.68M 0.86M 1.01M - -
Long term debt total - - 0.16M - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Investments 0.00000M -40.00694M -0.00183M 0.00000M 0.00000M
Change to liabilities 0.53M 0.13M -0.68526M 1.41M 0.97M
Total cashflows from investing activities - -40.00694M -0.00183M -0.00183M -0.00183M
Net borrowings - -0.17247M 0.16M 0.16M 0.16M
Total cash from financing activities 0.00000M 120.47M 22.90M 11.15M 17.30M
Change to operating activities 0.35M -2.13813M -0.00966M 0.24M 0.36M
Net income -33.64065M -23.05443M -17.54809M -15.56214M -12.53664M
Change in cash -28.36126M 56.21M 5.97M -1.29020M 5.98M
Begin period cash flow 70.07M 13.86M 7.89M 9.18M 3.20M
End period cash flow 41.71M 70.07M 13.86M 7.89M 9.18M
Total cash from operating activities -28.36126M -24.25041M -16.93066M -12.43775M -11.31814M
Issuance of capital stock 0.00000M 89.43M 15.58M 11.12M 16.17M
Depreciation 0.18M 0.16M 0.15M 0.00089M 0.00175M
Other cashflows from investing activities - -40.00000M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - 0.82M -0.81834M
Sale purchase of stock - 120.64M 7.16M 0.02M 17.30M
Other cashflows from financing activities - 31.21M 7.32M 0.02M 1.13M
Change to netincome 4.48M 1.29M 0.80M 0.72M 0.71M
Capital expenditures 0.00000M 40.01M 0.00183M 0.00183M 0.00183M
Change receivables - -0.08800M 0.02M 0.83M -0.80270M
Cash flows other operating 0.27M -2.52776M 0.48M 0.17M 0.54M
Exchange rate changes - - - - -
Cash and cash equivalents changes -28.36126M 56.21M 5.97M -1.29020M 5.98M
Change in working capital 0.24M -2.71727M -0.86697M 2.20M 0.51M
Stock based compensation 3.91M 1.45M 0.80M 0.72M 0.78M
Other non cash items 0.38M 0.07M 0.53M 0.21M 0.38M
Free cash flow -28.36126M -64.25735M -16.93249M -12.43775M -11.31814M


  • Previous Close 0.77
  • Market Cap126.58M
  • Volume312935
  • P/E Ratio-
  • Dividend Yield0.0%
  • EBITDA-34.15404M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM0.0
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.2

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Citius Pharmaceuticals Inc
0.02 2.61% 0.79 0.0 1.08 0.0 1.28 0.0 -2.751
Novo Nordisk A/S
3.64 3.01% 124.57 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
5.12 4.29% 124.40 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
7.83 1.87% 427.46 30.40 24.75 10.68 6.25 9.52 20.36
1.03 1.11% 93.74 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News


Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals Inc

11 Commerce Drive, Cranford, NJ, United States, 07016

Key Executives

Name Title Year Born
Mr. Leonard L. Mazur Co-Founder, CEO, Chairman & Sec. 1945
Mr. Myron Z. Holubiak Co-Founder & Exec. Vice Chairman 1947
Mr. Jaime Bartushak Chief Bus. Officer, CFO & Chief Accounting Officer 1968
Dr. Myron S. Czuczman M.D. Exec. VP & Chief Medical Officer 1960
Mr. Gary F. Talarico Exec. VP of Operations 1955
Ms. Ilanit Allen VP of Investor Relations & Corp. Communications NA
Dr. Alan Lader Ph.D. Sr. VP & Head of Clinical Operations and Quality Assurance NA
Mr. Dhananjay G. Wadekar Sr. VP of Bus. Strategy 1954
Mr. Kelly Creighton Ph.D. Exec. VP of Chemistry, Manufacturing & Controls NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).